The Beachbody Company, Inc. Class A Common Stock

BODI

The Beachbody Company, Inc. (BODI) is a fitness and wellness company that offers home workout programs, nutritional products, and related support services. Known for popular programs like P90X and Insanity, Beachbody has built a brand centered around at-home fitness solutions and community engagement, leveraging digital streaming platforms to reach a global audience.

$10.11 -0.52 (-4.92%)
🚫 The Beachbody Company, Inc. Class A Common Stock does not pay dividends

Company News

The Beachbody Company, Inc. (BODI) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research • Zacks Equity Research • May 6, 2024

The Beachbody Company (BODI) delivered earnings and revenue surprises of -0.52% and 4.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

The Beachbody Company, Inc. (BODI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks Investment Research • Zacks Equity Research • April 29, 2024

The Beachbody Company (BODI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga • Avi Kapoor • March 12, 2024

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losses of 4 cents per share which beat the analyst consensus estimate of losses of 10 cents by 60%. Quarterly sales came in at $171.1 million, beating the analyst consensus estimate of $167.676 million by 2.04%...

Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday
Benzinga • Avi Kapoor • March 12, 2024

U.S. stocks were higher, with the Dow Jones index surging more than 200 points on Tuesday. Shares of Bioventus Inc. (NASDAQ: BVS) rose sharply during Tuesday’s session after the company reported better-than-expected quarterly financial results and issued FY24 net sales guidance above estimates. Bioventus posted adjusted earnings of 7 cents per...

Related Companies